Amyotrophic Lateral Sclerosis

Assessing the role of measuring plasma neurofilament light levels in ALS 1:58
Assessing the role of measuring plasma neurofilament light levels in ALS
Nigel Leigh • 17 Mar 2022
AMD3100 in animal models of ALS and MS 1:11
AMD3100 in animal models of ALS and MS
Beka Solomon • 17 Mar 2022
Correlation between synaptic density and cognitive issues in ALS 6:28
Correlation between synaptic density and cognitive issues in ALS
Anna Sanchez Avila • 8 Mar 2022
How can the gut microbiome modulate the peripheral and brain immune systems? 4:45
How can the gut microbiome modulate the peripheral and brain immune systems?
Giulio Pasinetti • 18 Mar 2022
Improving ALS diagnosis: the Gold Coast criteria and the role of TMS 2:44
Improving ALS diagnosis: the Gold Coast criteria and the role of TMS
Matthew Kiernan • 4 Apr 2022
Ex vivo gene therapy for neurodegenerative diseases 2:20
Ex vivo gene therapy for neurodegenerative diseases
Clive Svendsen • 15 Mar 2022
Unanswered questions in ALS research 1:44
Unanswered questions in ALS research
Clive Svendsen • 15 Mar 2022
Phase II and III studies of CNM-Au8 in ALS 1:32
Phase II and III studies of CNM-Au8 in ALS
Robert Glanzman • 13 Oct 2021
Gene-based therapies for neurodegenerative & neuromuscular diseases 3:23
Gene-based therapies for neurodegenerative & neuromuscular diseases
Aida Abu-Baker • 11 Oct 2021
How does C9orf72 expansion impact protein degradation pathways in FTLD and ALS? 4:02
How does C9orf72 expansion impact protein degradation pathways in FTLD and ALS?
Annakaisa Haapasalo • 16 Sep 2021
A novel genetic marker to detect C9orf72 repeat expansion carriers 3:43
A novel genetic marker to detect C9orf72 repeat expansion carriers
Annakaisa Haapasalo • 16 Sep 2021
Outcome measures in motor neuron diseases and neuropathies 3:03
Outcome measures in motor neuron diseases and neuropathies
Marianne de Visser • 28 Sep 2021
Novel outcome measures for ALS and SMA 3:26
Novel outcome measures for ALS and SMA
Marianne de Visser • 28 Sep 2021
Using antibodies and intrabodies to target pathogenic TDP-43 in ALS 6:05
Using antibodies and intrabodies to target pathogenic TDP-43 in ALS
Neil Cashman • 2 Aug 2021
MS research from EAN 2021 2:11
MS research from EAN 2021
Massimo Filippi • 17 Jun 2021
Collaboration between neurology and palliative care services in ALS 2:06
Collaboration between neurology and palliative care services in ALS
David Oliver • 11 Jun 2021
The content of VJNeurology is intended for healthcare professionals